Literature DB >> 26695516

P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration.

Dragana Stokanovic1, Valentina N Nikolic, Sandra S Konstantinovic, Jelena B Zvezdanovic, Jelena Lilic, Svetlana R Apostolovic, Milan Pavlovic, Vladimir S Zivkovic, Tatjana Jevtovic-Stoimenov, Slobodan M Jankovic.   

Abstract

BACKGROUND/AIMS: One of the most common polymorphisms of ABCB1 gene, a synonymous mutation C3435T (rs1045642), is associated with increased in vivo activity. The main goal of this study was to determine the association of C3435T polymorphism with clopidogrel and 2-oxo-clopidogrel concentrations in plasma.
METHODS: The patients were recruited upon acute myocardial infarction diagnosis. They were all tested for ABCB1 C3435T polymorphism. In plasma, drawn 1 h after the drug administration, concentrations of clopidogrel and 2-oxo-clopidogrel were measured using UHPLC-DAD-MS analysis.
RESULTS: Due to differences in the maintenance doses, we have calculated the dose-adjusted concentrations of clopidogrel (0.2 ng/ml/mg (0.1-0.4)) and 2-oxo-clopidogrel (2.1 ng/ml/mg (0.5-4.6)). Patients carrying at least one C allele achieved significantly higher serum concentration of clopidogrel (p < 0.001), as well as dose-adjusted clopidogrel (p < 0.001) and 2-oxo-clopidogrel concentrations (p < 0.05).
CONCLUSION: The ABCB1 3435CC genotype is associated with increased clopidogrel and 2-oxo-clopidogrel dose-adjusted concentrations. Therefore, the ABCB1 C3435T genotyping should be one of the parameters taken into account when deciding about the dosing regimen of clopidogrel.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26695516     DOI: 10.1159/000442712

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

1.  Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.

Authors:  Marta Karaźniewicz-Łada; Dagmara Krzyżańska; Dorota Danielak; Janusz Rzeźniczak; Franciszek Główka; Marek Słomczyński; Paweł Burchardt
Journal:  Eur J Clin Pharmacol       Date:  2020-01-02       Impact factor: 2.953

Review 2.  Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.

Authors:  Yan-Jiao Zhang; Mu-Peng Li; Jie Tang; Xiao-Ping Chen
Journal:  Int J Environ Res Public Health       Date:  2017-03-14       Impact factor: 3.390

3.  A SNP involved in alternative splicing of ABCB1 is associated with clopidogrel resistance in coronary heart disease in Chinese population.

Authors:  Shasha Zhang; Jing Wang; Anan Zhang; Xiaowei Zhang; Tao You; Dingxiong Xie; Wenke Yang; Yuhong Chen; Xuetian Zhang; Cuixia Di; Xiaodong Xie
Journal:  Aging (Albany NY)       Date:  2020-11-20       Impact factor: 5.682

4.  The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.

Authors:  Tingting Wang; Hongjian Li; Fengxia Wang; Li Sun; Luhai Yu
Journal:  Eur J Clin Pharmacol       Date:  2021-06-23       Impact factor: 2.953

5.  ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1) polymorphism and clopidogrel concentration in acute coronary syndrome: molecular change can explain the observed therapeutic concentration.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Anatol J Cardiol       Date:  2016-04       Impact factor: 1.596

6.  CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.

Authors:  Tingting Wang; Ting Zhao; Sichen Bao; Li Jia; Jie Feng; Aiping Yu; Li Sun; Xihong Guo; Hongjian Li; Luhai Yu
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.